Update in the epidemiology, prophylaxis, and treatment of fungal infections in patients with hematologic disorders

Leukemia and Lymphoma

Volumn 45, Issue 4, 2004, Pages 669-680

  Hayes Lattin, Brandon ^a   Maziarz, Richard T ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Bone marrow transplantation; Leukemia lymphoma; Mycoses; Neutropenia; Opportunistic infection

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOFETILIDE; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; MICONAZOLE; MIDAZOLAM; NYSTATIN; PHENYTOIN; PIMOZIDE; POSACONAZOLE; QUINIDINE; RAPAMYCIN; RAVUCONAZOLE; SCH 56692; SIMVASTATIN; TACROLIMUS; TRIAZOLAM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG COST; DRUG FORMULATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; FUNGUS CULTURE; FUSARIUM; HEMATOLOGIC MALIGNANCY; HUMAN; INCIDENCE; INFUSION REACTION; MYCOSIS; NEPHROTOXICITY; PHOTOSENSITIVITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; VISUAL HALLUCINATION; VISUAL IMPAIRMENT;

ANTIFUNGAL AGENTS; HEMATOLOGIC DISEASES; HUMANS; MYCOSES; OPPORTUNISTIC INFECTIONS; TREATMENT OUTCOME;

EID: 1342344863     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190310001625719     Document Type: Review

References (121)

1. Laverdiere, M., Rotstein, C., Bow, E.J., Roberts, R.S., Ioannou, S., Carr, D., et al. (2000) "Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. The Canadian Fluconazole Study", J. Antimicrob. Chemother., 46, 1001-1008.
2. Martino, P., Girmenia, C., Micozzi, A., De Bernardis, F., Boccanera, M. and Cassone, A. (1994) "Prospective study of Candida colonization, use of empiric amphotericin B and development of invasive mycosis in neutropenic patients", Eur. J. Clin. Microbiol. Infect. Dis., 13, 797-804.
3. Pittet, D., Monod, M., Suter, P.M., Frenk, E. and Auckenthaler, R. (1994) "Candida colonization and subsequent infections in critically ill surgical patients", Ann. Surg., 220, 751-758.
4. Girmenia, C. and Martino, P. (1998) "Fluconazole and the changing epidemiology of candidemia", Clin. Infect. Dis., 27, 232-234.
5. Weems, J.J., Jr., Davis, B.J., Tablan, O.C., Kaufman, L. and Martone, W.J. (1987) "Construction activity: an independent risk factor for invasive aspergillosis and zygomycosis in patients with hematologic malignancy", Infect Control, 8, 71-75.
6. Krasinski, K., Holzman, R.S., Hanna, B., Greco, M.A., Graff, M. and Bhogal, M. (1985) "Nosocomial fungal infection during hospital renovation", Infect Control, 6, 278-282.
7. Sarubbi, F.A., Jr., Kopf, H.B., Wilson, M.B., McGinnis, M.R. and Rutala, W.A. (1982) "Increased recovery of Aspergillus flavus from respiratory specimens during hospital construction", Am. Rev. Respir. Dis., 125, 33-38.
8. Anaissie, E.J., Stratton, S.L., Dignani, M.C., Lee, C.K., Summerbell, R.C., Rex, J.H., et al. (2003) "Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies", Blood, 101, 2542-2546.
9. Anaissie, E.J. and Costa, S.F. (2001) "Nosocomial aspergillosis is waterborne", Clin. Infect. Dis., 33, 1546-1548.
10. Warris, A., Voss, A., Abrahamsen, T.G. and Verweij, P.E. (2002) "Contamination of hospital water with Aspergillus fumigatus and other molds", Clin. Infect. Dis., 34, 1159-1160.
11. Groll, A.H., Shah, P.M., Mentzel, C., Schneider, M., Just-Nuebling, G. and Huebner, K. (1996) "Trends in the postmortem epidemiology of invasive fungal infections at a university hospital", J. Infect., 33, 23-32.
12. Viscoli, C., Girmenia, C., Marinus, A., Collette, L., Martino, P., Vandercam, B., et al. (1999) "Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)", Clin. Infect. Dis., 28, 1071-1079.
13. Rotstein, C., Bow, E.J., Laverdiere, M., Ioannou, S., Carr, D. and Moghaddam, N. (1999) "Randomized placebo-controlled trial of fluconazole prophylaxis for neutropervic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group", Clin. Infect. Dis., 28, 331-340.
14. Kanda, Y., Yamamoto, R., Chizuka, A., Hamaki, T., Suguro, M., Arai, C., et al. (2000) "Prophylactic action of oral fluconazole against fungal infection in neutropervic patients. A meta-analysis of 16 randomized, controlled trials", Cancer, 89, 1611-1625.
15. Bow, E.J., Laverdiere, M., Lussier, N., Rotstein, C., Cheang, M.S. and Ioannou, S. (2002) "Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials", Cancer, 94, 3230-3246.
16. Passweg, J.R., Rowlings, P.A., Atkinson, K.A., Barrett, A.J., Gale, R.P., Gratwohl, A., et al. (1998) "Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukemia", Bone Marrow Transplant., 21, 1231-1238.
17. Fukuda, T., Boeckh, M., Carter, R.A., Sandmaier, B.M., Maris, M.B., Maloney, D.G., et al. (2003) "Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning", Blood, 102, 827-833.
18. Marr, K.A., Carter, R.A., Crippa, F., Wald, A. and Corey, L. (2002) "Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients", Clin. Infect. Dis., 34, 909-917.
19. Jantunen, E., Ruutu, P., Niskanen, L., Volin, L., Parkkali, T., Koukila-Kahkola, P., et al. (1997) "Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients", Bone Marrow Transplant., 19, 801-808.
20. Baddley, J.W., Stroud, T.P., Salzman, D. and Pappas, P.G. (2001) "Invasive mold infections in allogeneic bone marrow transplant recipients", Clin. Infect. Dis., 32, 1319-1324.
21. Martino, R., Subira, M., Rovira, M., Solano, C., Vazquez, L., Sanz, G.F., et al. (2002) "Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients", Br. J. Haematol., 116, 475-482.
22. Grow, W.B., Moreb, J.S., Roque, D., Manion, K., Leather, H., Reddy, V., et al. (2002) "Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital", Bone Marrow Transplant., 29, 15-19.
23. van Burik, J.H., Leisenring, W., Myerson, D., Hackman, R.C., Shulman, H.M., Sale, G.E., et al. (1998) "The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients", Medicine (Baltimore), 77, 246-254.
24. Marr, K.A., Seidel, K., White, T.C. and Bowden, R.A. (2000) "Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole", J. Infect. Dis., 181, 309-316.
25. Trick, W.E., Fridkin, S.K., Edwards, J.R., Hajjeh, R.A. and Gaynes, R.P. (2002) "Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999", Clin. Infect. Dis., 35, 627-630.
26. Pfaller, M.A., Diekema, D.J., Jones, R.N., Messer, S.A. and Hollis, R.J. (2002) "Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000", J. Clin. Microbiol., 40, 852-856.
27. Levin, A.S., Costa, S.F., Mussi, N.S., Basso, M., Sinto, S.I., Machado, C., et al. (1998) "Candida parapsilosis fungemia associated with implantable and semi-implantable central venous catheters and the hands of healthcare workers", Diagn. Microbiol. Infect. Dis., 30, 243-249.
28. Lin, S.J., Schranz, J. and Teutsch, S.M. (2001) "Aspergillosis case-fatality rate: systematic review of the literature", Clin. Infect. Dis., 32, 358-366.
29. Marr, K.A., Carter, R.A., Boeckh, M., Martin, P. and Corey, L. (2002) "Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors", Blood, 100, 4358-4366.
30. Wald, A., Leisenring, W., van Burik, J.A. and Bowden, R.A. (1997) "Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation", J. Infect. Dis., 175, 1459-1466.
31. Saugier-Veber, P., Devergie, A., Sulahian, A., Ribaud, P., Traore, F., Bourdeau-Esperou, H., et al. (1993) "Epidemiology and diagnosis of invasive pulmonary aspergillosis in bone marrow transplant patients: results of a 5 year retrospective study", Bone Marrow Transplant., 12, 121-124.
32. Lewis, R.E., Torres, H.A., May, G.S., Raad, I.I., Thornby, J., Rolston, K.V.I., et al. (2002) [M-1491] In vitro susceptibility and tolerance of Aspergillus species (spp) in a tertiary care center: correlation with invasive aspergillosis (IA) and its outcome. San Diego: ICAAC.
33. Walsh, T.J., Roden, M., Nelson, L., Knudson, T., Venzon, D., Segal, B., et al. (2002) [M-1233] Invasive fungal infections complicating non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT). San Diego: ICAAC.
34. Ascioglu, S., Rex, J.H., de Pauw, B., Bennett, J.E., Bille, J., Crokaert, F., et al. (2002) "Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus", Clin. Infect. Dis., 34, 7-14.
35. Chumpitazi, B.F., Pinel, C., Lebeau, B., Ambroise-Thomas, P. and Grillot, R. (2000) "Aspergillus fumigatus antigen detection in sera from patients at risk for invasive aspergillosis", J. Clin. Microbiol., 38, 438-443.
36. Maertens, J., Verhaegen, J., Lagrou, K., Van Eldere, J. and Boogaerts, M. (2001) "Screening for circulating galactomannan as a noninvasive diagnostic too for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation", Blood, 97, 1604-1610.
37. Verweij, P.E., Poulain, D., Obayashi, T., Patterson, T.F., Denning, D.W. and Ponton, J. (1998) "Current trends in the detection of antigenaemia, metabolites and cell wall markers for the diagnosis and therapeutic monitoring of fungal infections", Med. Mycol., 36 Suppl 1, 146-155.
38. Maertens, J., Verhaegen, J., Demuynck, H., Brock, P., Verhoef, G., Vandenberghe, P., et al. (1999) "Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis", J. Clin. Microbiol., 37, 3223-3228.
39. Herbrecht, R., Letscher-Bru, V., Oprea, C., Lioure, B., Waller, J., Campos, F., et al. (2002) "Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients", J. Clin. Oncol., 20, 1898-1906.
40. Pinel, C., Fricker-Hidalgo, H., Lebeau, B., Garban, F., Hamidfar, R., Ambroise-Thomas, P., et al. (2003) "Detection of circulating Aspergillus fumigatus galactomannan: value and limits of the platelia test for diagnosing invasive aspergillosis", J. Clin. Microbiol., 41, 2184-2186.
41. Odabasi, Z., Mattiuzzi, G., Ostrosky-Zeichner, L., Estey, E., Kantarjian, H. and Rex, J.H. (2002) [M-902] Detection of (1,3)-β-D-glucan (BG) in the serum of leukemia patients (pts) with invasive fungal infections (IFI). San Diego: ICAAC.
42. Lin, M.T., Lu, H.C. and Chen, W.L. (2001) "Improving efficacy of antifungal therapy by polymerase chain reaction-based strategy among febrile patients with neutropenia and cancer", Clin. Infect. Dis., 33, 1621-1627.
43. Einsele, H., Hebart, H., Roller, G., Loffler, J., Rothenhofer, I., Muller, C.A., et al. (1997) "Detection and identification of fungal pathogens in blood by using molecular probes", J. Clin. Microbiol., 35, 1353-1360.
44. Rex, J.H., Pfaller, M.A., Walsh, T.J., Chaturvedi, V., Espinel-Ingroff, A., Ghannoum, M.A., et al. (2001) "Antifungal susceptibility testing: practical aspects and current challenges", Clin. Microbiol. Rev., 14, 643-658.
45. Arthington-Skaggs, B.A., Lee-Yang, W., Ciblak, M.A., Frade, J.P., Brandt, M.E., Hajjeh, R.A., et al. (2002) "Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates", Antimicrob. Agents Chemother., 46, 2477-2481.
46. Hawser, S.P., Jessup, C., Vitullo, J. and Ghannoum, M.A. (2001) "Utility of 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenyl-amino carbonyl]-2H-tet razolium hydroxide (XTT) and minimum effective concentration assays in the determination of antifungal susceptibility of Aspergillus fumigatus to the lipopeptide class compounds", J. Clin. Microbiol., 39, 2738-2741.
47. Balajee, S.A. and Marr, K.A. (2002) "Conidial viability assay for rapid susceptibility testing of Aspergillus species", J. Clin. Microbiol., 40, 2741-2745.
48. Arthington-Skaggs, B.A., Warnock, D.W. and Morrison, C.J. (2000) "Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis", Antimicrob. Agents Chemother., 44, 2081-2085.
49. Kontoyiannis, D.P. and Lewis, R.E. (2002) "Antifungal drug resistance of pathogenic fungi", Lancet, 359, 1135-1144.
50. Balkis, M.M., Leidich, S.D., Mukherjee, P.K. and Ghannoum, M.A. (2002) "Mechanisms of fungal resistance: an overview", Drugs, 62, 1025-1040.
51. Woolley, I., Curtis, D., Szer, J., Fairley, C., Vujovic, O., Ugoni, A., et al. (1997) "High dose cytosine arabinoside is a major risk factor for the development of hepatosplenic candidiasis in patients with leukemia", Leuk. Lymphoma, 27, 469-474.
52. Gerson, S.L., Talbot, G.H., Hurwitz, S., Strom, B.L., Lusk, E.J. and Cassileth, P.A. (1984) "Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia", Ann. Intern. Med., 100, 345-351.
53. Segal, B.H., Bow, E.J. and Menichetti, F. (2002) "Fungal infections in nontransplant patients with hematologic malignancies", Infect. Dis. Clin. North Am., 16, 935-964, vii.
54. Ng, T.T., Robson, G.D. and Denning, D.W. (1994) "Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis", Microbiology, 140, 2475-2479.
55. Klepser, M.E., Wolfe, E.J., Jones, R.N., Nightingale, C.H. and Pfaller, M.A. (1997) "Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans", Antimicrob. Agents Chemother., 41, 1392-1395.
56. Andes, D., Stamsted, T. and Conklin, R. (2001) "Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model", Antimicrob. Agents Chemother., 45, 922-926.
57. Prentice, H.G., Hann, I.M., Herbrecht, R., Aoun, M., Kvaloy, S., Catovsky, D., et al. (1997) "A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients", Br. J. Haematol., 98, 711-718.
58. Walsh, T.J., Finberg, R.W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., et al. (1999) "Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group", N. Engl. J. Med., 340, 764-771.
59. Leenders, A.C., Daenen, S., Jansen, R.L., Hop, W.C., Lowenberg, B., Wijermans, P.W., et al. (1998) "Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections", Br. J. Haematol., 103, 205-212.
60. Leenders, A.C., Reiss, P., Portegies, P., Clezy, K., Hop, W.C., Hoy, J., et al. (1997) "Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis", Aids, 11, 1463-1471.
61. Bowden, R., Chandrasekar, P., White, M.H., Li, X., Pietrelli, L., Gurwith, M., et al. (2002) "A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immuno-compromised patients", Clin. Infect. Dis., 35, 359-366.
62. Johnson, P.C., Wheat, L.J., Cloud, G.A., Goldman, M., Lancaster, D., Bamberger, D.M., et al. (2002) "Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS", Ann. Intern. Med., 137, 105-109.
63. Wingard, J.R. (2002) "Lipid formulations of amphotericins: are you a lumper or a splitter?", Clin. Infect. Dis., 35, 891-895.
64. Ringden, O., Meunier, F., Tollemar, J., Ricci, P., Tura, S., Kuse, E., et al. (1991) "Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients", J. Antimicrob. Chemother., 28, 73-82.
65. Walsh, T.J., Hiemenz, J.W., Seibel, N.L., Perfect, J.R., Horwith, G., Lee, L., et al. (1998) "Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases", Clin. Infect. Dis., 26, 1383-1396.
66. White, M.H., Anaissie, E.J., Kusne, S., Wingard, J.R., Hiemenz, J.W., Cantor, A., et al. (1997) "Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis", Clin. Infect. Dis., 24, 635-642.
67. Cagnoni, P.J., Walsh, T.J., Prendergast, M.M., Bodensteiner, D., Hiemenz, S., Greenberg, R.N., et al. (2000) "Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients", J. Clin. Oncol., 18, 2476-2483.
68. Wingard, J.R., Kubilis, P., Lee, L., Yee, G., White, M., Walshe, L., et al. (1999) "Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis", Clin. Infect. Dis., 29, 1402-1407.
69. Micromedex Healthcare Series. Vol. 2003: Thomson.
70. Marr, K.A. (2002) Infections in Transplant Patients. San Diego: ICAAC.
71. Gangwar, M., Doney, A., Cole, R., Sheehan, D.J. and Chaturvedi, V. (2002) [M-216] Study of Aspergillus fumigatus-Antifungal interactions by fluorescent probes & image analysis. San Diego: ICAAC.
72. Johnson, L.B. and Kauffman, C.A. (2003) "Voriconazole: a new triazole antifungal agent", Clin. Infect. Dis., 36, 630-637.
73. Vfend prescribing information. Vol. 2002: Pfizer.
74. Pfaller, M.A., Messer, S.A., Hollis, R.J. and Jones, R.N. (2002) "Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000", Antimicrob. Agents Chemother., 46, 1032-1037.
75. Pfaller, M.A., Messer, S.A., Hollis, R.J., Jones, R.N. and Diekema, D.J. (2002) "In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.", Antimicrob. Agents Chemother., 46, 1723-1727.
76. Abruzzo, G.K., Flattery, A.M., Gill, C.J., Kong, L., Smith, J.G., Pikounis, V.B., et al. (1997) "Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis", Antimicrob. Agents Chemother., 41, 2333-2338.
77. Cancidas prescribing information. Vol. 2002: Merck.
78. Goodman, J.L., Winston, D.J., Greenfield, R.A., Chandrasekar, P.H., Fox, B., Kaizer, H., et al. (1992) "A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation", N. Engl. J. Med., 326, 845-851.
79. Slavin, M.A., Osborne, B., Adams, R., Levenstein, M.J., Schoch, H.G., Feldman, A.R., et al. (1995) "Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study", J. Infect. Dis., 171, 1545-1552.
80. MacMillan, M.L., Goodman, J.L., DeFor, T.E. and Weisdorf, D.J. (2002) "Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy", Am. J. Med., 112, 369-379.
81. Johansen, H.K. and Gotzsche, P.C. (2002) "Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients", Cochrane Database of Systematic Reviews, 3, CD000239.
82. Gotzsche, P.C. and Johansen, H.K. (2002) "Routine versus selective antifungal administration for control of fungal infections in patients with cancer", Cochrane Database Syst Rev, CD000026.
83. Cornely, O.A., Ullmann, A.J. and Karthaus, M. (2003) "Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies", Blood, 101, 3365-3372.
84. Morgenstern, G.R., Prentice, A.G., Prentice, H.G., Ropner, J.E., Schey, S.A. and Warnock, D.W. (1999) "A randomized Controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group", Br. J. Haematol., 105, 901-911.
85. Winston, D.J., Maziarz, R.T., Chandrasekar, P.H., Lazarus, H.M., Goldman, M., Blumer, J.L., et al. (2003) "Intravenous and Oral Itraconazole versus Intravenous and Oral Fluconazole for Long-Term Antifungal Prophylaxis in Allogeneic Hematopoietic Stem-Cell Transplant Recipients. A Multicenter, Randomized Trial", Ann. Intern. Med., 138, 705-713.
86. Marr, K.A., Crippa, F., Leisenring, W., Hoyle, M., Boeckh, M., Balajee, A., et al. (2003) "Itraconazole versus fluconazole for prevention of fungal infections in allogencic stem cell transplant patients", Blood, DOI 10.1182/blood-2003-08-2644. Pre-published October 2, 2003. http://www.bloodjournal.org/cgi/reprint/2003-08-2644vl.pdf
87. van Burik, J., Ratanatharathorn, V., Lipton, J., Miller, C., Bunin, N. and Walsh, T.J. (2002) [M-1238] Randomized, double-blind trial of micafungin (MI) versus fluconazole (FL) for prophylaxis of invasive fungal infections in patients (pts) undergoing hematopoietic stem cell transplant (HSCT), NIAID/BAMSG protocol 46. San Diego: ICAAC.
88. Offner, F., Cordonnier, C., Ljungman, P., Prentice, H.G., Engelhard, D., De Bacquer, D., et al. (1998) "Impact of previous aspergillosis on the outcome of bone marrow transplantation", Clin. Infect. Dis., 26, 1098-1103.
89. Cordonnier, C., Pautas, C., Bastie, J., Castaigne, S., Maury, S., Bretagne, S., et al. (2002) Voriconazole as secondary prophylaxis for leukemic patients with previous invasive fungal diseases and going to a new at-risk phase. San Diego: ICAAC.
90. De Pauw, B.E., Deresinski, S.C., Feld, R., Lane-Allman, E.F. and Donnelly, J.P. (1994) "Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group", Ann. Intern. Med., 120, 834-844.
91. Pizzo, P.A., Robichaud, K.J., Gill, F.A. and Witebsky, F.G. (1982) "Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia", Am. J. Med., 72, 101-111.
92. EORTC International Antimicrobial Therapy Cooperative Group(1989) "Empiric antifungal therapy in febrile granulocytopenic patients", Am. J. Med., 86, 668-672.
93. Hughes, W.T., Armstrong, D., Bodey, G.P., Brown, A.E., Edwards, J.E., Feld, R., et al. (1997) "1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America", Clin. Infect. Dis., 25, 551-573.
94. Boogaerts, M., Winston, D.J., Bow, E.J., Garber, G., Reboli, A.C., Schwarer, A.P., et al. (2001) "Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial", Ann. Intern. Med., 135, 412-422.
95. Walsh, T.J., Pappas, P., Winston, D.J., Lazarus, H.M., Petersen, F., Raffalli, J., et al. (2002) "Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever", N. Engl. J. Med., 346, 225-234.
96. Herbrecht, R., Denning, D.W., Patterson, T.F., Bennett, J.E., Greene, R.E., Oestmann, J.W., et al. (2002) "Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis", N. Engl. J. Med., 347, 408-415.
97. Denning, D.W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., et al. (2002) "Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis", Clin. Infect. Dis., 34, 563-571.
98. Walsh, T.J., Lutsar, I., Driscoll, T., Dupont, B., Roden, M., Ghahramani, P., et al. (2002) "Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children", Pediatr. Infect. Dis. J., 21, 240-248.
99. Denning, D.W. (1998) " Invasive aspergillosis", Clin. Infect. Dis., 26, 781-803; quiz 804-785.
100. Maertens, J., Raad, I., Petrikkos, G., Selleslag, D., Petersen, F., Sable, C., et al. (2002) Update of the multicenter noncomparative study of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory (R) or intolerant (I) to other antijungal agents: analysis of 90 patients. San Diego: 42nd ICAAC.
101. Sanz-Rodriguez, C., Aguado, J.M., Cisneros, J.M., Vivancos, R. and Gonzalez-Esteban, J. (2002) [M-895] Caspofungin therapy in documented fungal infections: Spanish experience before licensure of the drug. San Diego, CA: 42nd ICAAC.
102. Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A.L., Thompson-Moya, L., Smietana, J., et al. (2002) "Comparison of caspofungin and amphotericin B for invasive candidiasis", N. Engl. J. Med., 347, 2020-2029.
103. Te Dorsthorst, D.T.A., Mouton, J.W., Van der Lee, H.A.L. and Verweij, P.E. (2002) [M-850] In vitro interactions of antifungals against clinical Aspergillus isolates. San Diego: ICAAC.
104. Bachmann, S.P., Ramage, G., Fothergill, A.W., Rinaldi, M.G., Wickes, B.L., Patterson, T.F., et al. (2002) [M-1813] Combinations of antifungal agents against Candida albicans biofilms in vitro. San Diego: ICAAC.
105. Thiebaut, A., Antal, D., Breysse, M.C. and Pivot, C. (2002) [M-859] Refractory invasive fungal infections in patients (pts) with hematologic malignancies: Combination of new antifungal agents (voriconazole or caspofungin) with amphotericin B. San Diego: ICAAC.
106. Kontoyiannis, D.P., Hachem, R., Lewis, R.E., Rivero, G., Kantarjian, H. and Raad, I.I. (2002) [M-1820] Efficacy, and toxicity of the caspofungin/liposomal amphotericin B (CAS/LipoAMB) combination in documented or possible invasive aspergillosis (IA) in patients (Pts) with hematologic malignancies. San Diego: ICAAC.
107. Aliff, T.B., Maslak, P.G., Jurcic, J.G., Heaney, M.L., Cathcart, K.N., Sepkowitz, K.A., et al. (2003) "Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin", Cancer, 97, 1025-1032.
108. Perea, S., Gonzalez, G., Fothergill, A.W., Kirkpatrick, W.R., Rinaldi, M.G. and Patterson, T.F. (2002) "In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.", Antimicrob. Agents Chemother., 46, 3039-3041.
109. Kirkpatrick, W.R., Perea, S., Coco, B.J. and Patterson, T.F. (2002) "Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis", Antimicrob. Agents Chemother., 46, 2564-2568.
110. Gentina, T., De Botton, S., Alfandari, S., Delomez, J., Jaillard, S., Leroy, O., et al. (2002) [M-860] Combination antifungals for treatment of pulmonary invasive aspergillosis (IA) refractory to amphotericin B (AmB) in leukaemia patients. San Diego: ICAAC.
111. Rubin, M.A., Carroll, K.C. and Cahill, B.C. (2002) "Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans", Clin. Infect. Dis., 34, 1160-1161.
112. Kontoyiannis, D.P., Lewis, R.E., May, G.S., Albert, N.D. and Raad, I.I. (2002) [M-851] Sequential exposure of A. fumigatus to itraconazole (ITRA) and caspofungin (CAS): Evidence of enhanced in vitro activity of this combination. San Diego: ICAAC.
113. Cacciapuoti, A.F., Gurnani, M., Halpern, J., Gheyas, F., Hare, R. and Loebenberg, D. (2002) [M-1814] Combination treatment of posaconazole (POS) and amphotericin B (AmB) against Candida albicans in a mouse systemic infection model. San Diego: ICAAC.
114. Caillot, D., Casasnovas, O., Bernard, A., Couaillier, J.F., Durand, C., Cuisenier, B., et al. (1997) "Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery", J. Clin. Oncol., 15, 139-147.
115. Baron, O., Guillaume, B., Moreau, P., Germaud, P., Despins, P., De Lajartre, A.Y., et al. (1998) "Aggressive surgical management in localized pulmonary mycotic and nonmycotic infections for neutropenic patients with acute leukemia: report of eighteen cases", J. Thorac. Cardiovasc. Surg., 115, 63-68; discussion 68-69.
116. Caillot, D., Couaillier, J.F., Bernard, A., Casasnovas, O., Denning, D.W., Mannone, L, et al. (2001) "Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia", J. Clin. Oncol., 19, 253-259.
117. Hubel, K., Dale, D.C., Engert, A. and Liles, W.C. (2001) "Current status of granulocyte (neutrophil) transfusion therapy for infectious diseases", J. Infect. Dis., 183, 321-328.
118. Bhatia, S., McCullough, J., Perry, E.H., Clay, M., Ramsay, N.K. and Neglia, J.P. (1994) "Granulocyte transfusions: efficacy in treating fungal infections in neutropenic patients following bone marrow transplantation", Transfusion, 34, 226-232.
119. Price, T.H., Bowden, R.A., Boeckh, M., Bux, J., Nelson, K., Liles, W.C., et al. (2000) "Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation", Blood, 95, 3302-3309.
120. Peters, C., Minkov, M., Matthes-Martin, S., Potschger, U., Witt, V., Mann, G., et al. (1999) "Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised neutropenic patients", Br. J. Haematol., 106, 689-696.
121. Dignani, M.C., Anaissie, E.J., Hester, J.P., O'Brien, S., Vartivarian, S.E., Rex, J.H., et al. (1997) "Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study", Leukemia, 11, 1621-1630.